Eisai Inc.
Clinical trials sponsored by Eisai Inc., explained in plain language.
A pharmaceutical company focused on neurology and oncology, subsidiary of Eisai Co., Ltd.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a new drug play nice with common medicines? a trial investigates Results expected Nov 2026 (estimated)
- Double attack on Alzheimer's: new drug combo targets tau and amyloid Results expected Dec 2026 (estimated)
- Mining medical claims: a smarter way to spot Alzheimer's complications? Results expected Dec 2026 (estimated)
- New pill aims to keep narcolepsy patients awake and safe Results expected Feb 2027 (estimated)
- New drug combo shows promise for Hard-to-Treat cancers Results expected Mar 2027 (estimated)
-
New drug targets Hard-to-Treat breast cancers
Disease control CompletedThis phase 2 trial tests BB-1701, a drug that targets HER2 on breast cancer cells, in 56 people with advanced breast cancer that is HER2-positive or HER2-low. The study has two parts: first to find the best dose, then to see how well it shrinks tumors. Participants receive the dr…
Phase 2 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New combo therapy shows promise for advanced uterine cancer
Disease control CompletedThis study tested a combination of two drugs, lenvatinib and pembrolizumab, against standard chemotherapy in 827 people with advanced endometrial cancer that had worsened after initial treatment. The goal was to see if the combo could delay cancer growth and extend life. Results …
Phase 3 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New antibody shows promise in slowing Alzheimer's decline
Disease control CompletedThis study tested an experimental drug called lecanemab (BAN2401) in 856 people with early Alzheimer's disease, including those with mild cognitive impairment or mild dementia. Participants received different doses of the drug or a placebo every 2 or 4 weeks for 18 months. The go…
Phase 2 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug combo shows promise for Tough-to-Treat cancers
Disease control CompletedThis study tested a new drug called E7386 combined with the immunotherapy pembrolizumab (Keytruda) in 89 people with advanced melanoma, colorectal cancer, or liver cancer. The goal was to see if the combination is safe and can shrink tumors. Some participants with liver cancer al…
Phase 1/2 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Healthy men swallow radioactive pill to track Drug's journey
Knowledge-focused CompletedThis early-stage study gives 10 healthy men a single dose of the experimental drug E2086 with a radioactive tracer. Researchers will measure how much of the drug appears in blood, urine, and stool over time. The goal is to understand how the body breaks down and eliminates E2086,…
Phase 1 • Sponsor: Eisai Inc. • Aim: Knowledge-focused
Last updated Aug 23, 2026 00:00 UTC